Literature DB >> 9135079

The HGF receptor family: unconventional signal transducers for invasive cell growth.

P M Comoglio1, C Boccaccio.   

Abstract

The HGF receptor family includes tyrosine kinases encoded by three oncogenes: MET, SEA and RON. The members of this gene family share a unique functional feature: they mediate cell dissociation and motility ('scattering') in physiological conditions, and invasiveness in their activated versions. The Met, Ron and Sea receptors display a distinctive signal transduction behaviour. Unlike conventional growth factor receptors, their cytoplasmic tails contain a multifunctional docking site. Upon autophosphorylation, this sequence simultaneously binds and activates multiple SH2-containing transducers, including Ras and PI 3-kinase. A deregulated activation of this 'supersite' triggers a dramatic pleiotropic signal which is responsible for invasive cell growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9135079     DOI: 10.1046/j.1365-2443.1996.37037.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  19 in total

1.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  The MET axis as a therapeutic target.

Authors:  Martin Sattler; Ravi Salgia
Journal:  Update Cancer Ther       Date:  2009-04-01

3.  Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1.

Authors:  Urai Pongchairerk; Jun-Lin Guan; Vijittra Leardkamolkarn
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

4.  Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells.

Authors:  S J Holland; N W Gale; G D Gish; R A Roth; Z Songyang; L C Cantley; M Henkemeyer; G D Yancopoulos; T Pawson
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

5.  Met interacts with EGFR and Ron in canine osteosarcoma.

Authors:  J K McCleese; M D Bear; S K Kulp; C Mazcko; C Khanna; C A London
Journal:  Vet Comp Oncol       Date:  2011-12-08       Impact factor: 2.613

6.  A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.

Authors:  Aung Naing; Razelle Kurzrock; Laurel M Adams; Joseph F Kleha; Kevin H Laubscher; Peter L Bonate; Steven Weller; Colleen Fitzgerald; Yanmei Xu; Patricia M LoRusso
Journal:  Invest New Drugs       Date:  2010-09-15       Impact factor: 3.850

Review 7.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

8.  MUC20 suppresses the hepatocyte growth factor-induced Grb2-Ras pathway by binding to a multifunctional docking site of met.

Authors:  Toshio Higuchi; Takuya Orita; Ken Katsuya; Yoshiki Yamasaki; Kiyotaka Akiyama; Huiping Li; Tadashi Yamamoto; Yutaka Saito; Motonao Nakamura
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 9.  c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.

Authors:  Martin Sattler; Ravi Salgia
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

10.  The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis.

Authors:  Sara E Meyer; Glendon M Zinser; William D Stuart; Peterson Pathrose; Susan E Waltz
Journal:  Dev Biol       Date:  2009-07-01       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.